Back to search results

Long COVID Treatment Study: Maraviroc and Atorvastatin

This study is testing if a combination of two existing drugs, Maraviroc and Atorvastatin, can help people with Long COVID. Researchers want to see if this treatment can improve symptoms like fatigue, heart rate, blood pressure, digestion, breathing, dizziness, and thinking abilities. You may be able to join if you are between 18 and 65 years old and have been diagnosed with Long COVID, meaning you've had symptoms for at least two months, starting three months after your initial COVID-19 infection. The main goal is to see if fatigue improves after 12 weeks of treatment. The current status of this study is unclear, and it plans to enroll 252 participants.

Study design
This is a multi-center study where participants will be randomly assigned to receive either the study drugs or a placebo (an inactive substance), without knowing which they are getting. It aims to enroll 252 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Fatigue will be measured at the end of treatment, at week 12.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06974084

A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID

Not Yet Recruiting
PHASE2Ages 18–65InterventionalTreatment
HealthBio, Inc.
~252 participants
Updated 2026-06-18 on ClinicalTrials.gov
What's tested:Maraviroc (MVC)Atorvastatin, 10mg, 20mg, 40mgPlacebo, MaravirocPlacebo, Atorvastatin

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Fatigue
Measured over PROMIS Fatigue scores will be taken during screening (0-28 days before the first baseline) and at the EOT visit, week 12.

Conditions

Long COVID

Explore related trials

Post-Acute Sequelae of COVID-19

NCT06974084

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Arizona

    Tucson, Arizonastudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Brad Fox
[email protected]
623-824-9165
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Self-reported consumption \>14 drinks/week (males) or \>7 drinks/week (females), OR
Binge drinking (≥5 drinks on one occasion for males, ≥4 for females) ≥1 time per week, OR
Clinical judgment that alcohol use would interfere with study compliance or safety 15. Subjects with risk factors for myocardial ischemia/infarction, including but not limited to those with a prior history of MI, stroke, unstable angina, 16. Any significant disease or disorder, which, in the opinion of the Investigator, may either put the participants at risk 17. Azole antifungals (ketoconazole or itraconazole are not allowed) or macrolide antibiotics (clarithromycin is not allowed) 18. History of use of maraviroc and/or atorvastatin for the off-label treatment of Long COVID.

What this trial measures

  • FatiguePROMIS Fatigue scores will be taken during screening (0-28 days before the first baseline) and at the EOT visit, week 12.

    Fatigue will be measured via PROMIS Fatigue v1.0. The PROMIS Fatigue 10a assesses fatigue severity in the previous week. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The instrument translates the total raw score into a T-score with a mean of 50 and a standard deviation of 10. A score of 50 is the average for the United States general population (SD=10).